DDInter1238 DDInter1376
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. It was approved for the same indications in Canada in June 2022. Mogamuliz
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mogamulizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Mogamulizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Mogamulizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Mogamulizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Mogamulizumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Mogamulizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Mogamulizumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Mogamulizumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Mogamulizumab may lead to a major life threatening interaction when taken with Upadacitinib
Mogamulizumab may lead to a major life threatening interaction when taken with Cladribine